Hydroxyurea induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.
Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.
Cancer Research | Apoptosis and Cell Cycle
|Alternate Names||Hydroxycarbamide; Carrbamoyl Oxime; N-(Aminocarbonyl) Hydroxyamine; Oxyurea|
|Application Notes||Hydroxyurea induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.|
|Base Catalog Number||102023|
|Beilstein Registry Number||1741548|
|Biochemical Physiological Actions||Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.|
|Personal Protective Equipment||Eyeshields, Full-face particle respirator, Gloves, Respirator cartridge, Respirator filter|